loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Certificates of Suitability (CEPs) for cep_1999_099___rev_09 Active Pharmaceutical Ingredient (API) issued by the EDQM. Original Data: EDQM Database

    Client Virtual Booth
    Menu

    Centrient Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    Key Products KEY PRODUCTS

    INTERMEDIATES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    PharmaCompass Sponsored Ads

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 CENTRIENT PHARMACEUTICALS NETHERLANDS B.V. Delft NL (1)

    filter

    01 Nystatin, Powder or “micronised” (for extemporaneous oral suspension) (1)

    filter

    01 Netherlands (1)

    filter

    01 Valid (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    CENTRIENT PHARMACEUTICALS NETHERLAN...

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual BoothCentrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.
    Contact Supplier Contact Supplier
    Flag Netherlands
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Nystatin, Powder or “micronised” (for extemporaneou...

    PDF Supplier PDF
    URL Supplier Web Content
    CEP 1999-099 - Rev 09
    Valid
    Chemical
    2024-03-22
    517
    Centrient Pharmaceuticals

    EMWA 2024

    Not Confirmed

    envelop Contact Supplier

    Looking for Certificates of Suitability (CEPs) for CEP 1999-099 - Rev 09 of Centrient Pharmaceuticals Netherlands B.v. Delft Nl

    Looking for Certificates of Suitability (CEPs) for CEP 1999-099 - Rev 09 of Centrient Pharmaceuticals Netherlands B.v. Delft Nl 1

    20

    Centrient Pharmaceuticals Netherlands B.v. Delft Nl, based in Netherlands, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.

    They are recognized for Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    One of their significant offerings is Nystatin, Powder or “micronised” (for extemporaneous oral suspension), supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 1999-099 - Rev 09

    This Chemical Type CEP, issued on March 22, 2024, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.

    Substance Number 517 associated with this CEP further emphasizes

    Post Enquiry
    POST ENQUIRY